Inovio Pharmaceuticals, Inc has initiated a phase I/IIa clinical trial
to evaluate safety, immunogenicity and clinical responses of its
immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-
associated head and neck cancer. INO-3112 is a combination of Inovio's
lead active immunotherapy product, VGX-3100, and its proprietary immune
activator expressing interleukin-12 (IL-12). VGX-3100 is currently being
evaluated in a randomised phase II efficacy trial for the treatment of
high grade cervical dysplasia (pre-cancer).
No comments:
Post a Comment